Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Core Viewpoint - Novartis has announced an agreement to acquire Excellergy, Inc., enhancing its immunology strategy in food allergies and other IgE-driven diseases with the lead asset Exl-111, a next-generation anti-IgE therapy in Phase 1 [1][2][3] Group 1: Acquisition Details - The acquisition will involve a payment of up to USD 2 billion in upfront and milestone payments, expected to close in the second half of 2026, pending regulatory approvals [4] - Exl-111 is designed to provide faster and deeper suppression of IgE signaling, potentially improving symptom control and convenience for patients [3][2] Group 2: Product and Mechanism - Exl-111 builds on established IgE biology and aims to dissociate receptor-bound IgE, which could lead to enhanced disease control across various allergic conditions [3][2] - Preclinical studies and early clinical data suggest a differentiated profile for Exl-111, with sustained exposure consistent with its half-life-extended design [3] Group 3: Strategic Importance - The acquisition reflects Novartis's commitment to advancing innovative science in immunology, particularly in the field of allergic diseases [5] - Novartis aims to leverage its expertise in IgE biology to enhance its existing allergy portfolio and address a range of IgE-mediated diseases, including food allergies and chronic urticaria [2][3]